AI assistant
Active Biotech Share Issue/Capital Change 2026
3133_rns_2026-01-30_08810581-fc94-49e3-bc3e-c1a036fbc187.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
{0}------------------------------------------------
30 JANUARY 2026 11:30:00 CET
Number of shares and votes in Active Biotech
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 2,636,067,170 shares and votes in Active Biotech.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, [email protected] Hans Kolam, CFO, +46 46 19 20 44, [email protected]
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops firstin-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. A clinical Phase Ib/IIa study in multiple myeloma has been concluded. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-01-30 11:30 CET.